A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Conditions : Light Chain (AL) Amyloidosis Interventions : Biological: NXC-201; Drug: Dara-CyBorD Sponsors : Nexcella Inc.; Immix Biopharma, Inc. Not yet recruiting
Read the full article2d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Qualitative Study Protocol on Ethical Perceptions of Simulative Technologies in Long-Term Dementia Care
doi.org·44m agoAI predicts late breast cancer recurrence risk
yesilscience.com·1h ago
AI Medicare Denials Are Here to Stay
yesilscience.com·5h ago
A blind woman reached out and touched a tree she couldn’t see. She’d ‘heard’ it standing there.
Upworthy·6h ago
Leafy Greens May Cut COPD Risk by 16%, Large UK Study Finds
Science Sensei·6h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.